<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433236</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-051</org_study_id>
    <nct_id>NCT02433236</nct_id>
  </id_info>
  <brief_title>Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy</brief_title>
  <official_title>A Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib
      in approximately 25 subjects. The study will consist of 11 visits over 15 months.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study withdrawn prior to enrollment of first subject
  </why_stopped>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with mean change of Proteinuria as measured by spot urine protein/creatinine ratio (sPCR)</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>IGA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Fostamatinib Disodium tablet 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib Disodium tablet 100 milligram (mg) by mouth twice a day for 15 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fostamatinib Disodium tablet 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib Disodium tablet 150 milligram (mg) by mouth twice a day for 15 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib Disodium tablet 100 mg</intervention_name>
    <arm_group_label>Fostamatinib Disodium tablet 100 mg</arm_group_label>
    <other_name>Fostamatinib</other_name>
    <other_name>R788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib Disodium tablet 150 mg</intervention_name>
    <arm_group_label>Fostamatinib Disodium tablet 150 mg</arm_group_label>
    <other_name>Fostamatinib</other_name>
    <other_name>R788</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed Study C-938788-050, including having received a post-treatment renal biopsy,
             and having had a clinically meaningful response (i.e. decreased proteinuria or
             improved renal histology)

          -  Able and willing to give written informed consent

        Exclusion Criteria:

          -  Unresolved Grade 2 or greater toxicity in Study C-935788-050
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rigel Pharmaceuticals, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Rigel Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

